Zentalis(US:ZNTL) Prnewswireยท2025-02-04 20:05Core Viewpoint - Zentalis Pharmaceuticals is under investigation for potential securities fraud and unlawful business practices following a significant restructuring announcement and subsequent stock price decline [1][2]. Group 1: Company Actions - On January 28, 2025, Zentalis announced a restructuring of its business operations and research and development organization to support the late-stage development of its WEE1 inhibitor product candidate, azenosertib [2]. - The company aims to extend its cash runway beyond the anticipated data readout from the DENALI Part 2 study, expected by the end of 2026 [2]. - A workforce reduction is expected to be substantially completed in the second quarter of 2025 [2]. Group 2: Market Reaction - Following the restructuring announcement, Zentalis's stock price experienced a sharp decline during intraday trading on January 29, 2025 [2]. Group 3: Legal Context - Pomerantz LLP is investigating claims on behalf of Zentalis investors regarding possible securities fraud or other unlawful business practices by the company and its officers/directors [1].